Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 2429Neoplasms 1840Carcinoma, Non-Small-Cell Lung 1615Prostatic Neoplasms 1309Colorectal Neoplasms 1147Lung Neoplasms 991Neoplasm Metastasis 836Multiple Myeloma 801Leukemia, Myeloid, Acute 777Ovarian Neoplasms 682Pancreatic Neoplasms 667Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Recurrence 568Carcinoma, Hepatocellular 568Brain Neoplasms 529Glioblastoma 519Stomach Neoplasms 504Head and Neck Neoplasms 503Triple Negative Breast Neoplasms 472Lymphoma 462Uterine Cervical Neoplasms 454Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 419Lymphoma, Non-Hodgkin 392Endometrial Neoplasms 385Sarcoma 370Lymphoma, Follicular 358Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

Hizentra 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Common Variable Immunodeficiency × 1 year × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡